David M. Friedland, MD

Despite advances in the treatment of small-cell lung cancer during the 1970s, with the use of combination chemotherapy, and in the 1980s, with the combination of etoposide and cisplatin plus concurrent radiation

The treatment of advanced non-small-cell lung cancer has undergone incremental improvement over the last three decades of investigation. When this incremental history is reviewed, three distinct subdivisions emerge: (1) the minimal-activity era